
Dedication

To those persons in Cairns Hospital Integrated mental Health Service low-dependence unit, who continue to fill themselves by plastering butter on white bread and drinking copious cola beverages, thanks for the inspiration.

I would like to dedicate this book to the children, for whom, I believe that finding natural treatments for mental illness is of paramount importance into their future.
Acknowledgements

‘I suffered from Shizzophreenier. It seemed to spell my doom, as if I had emerged from a chrysalis, the natural human state, into another kind of creature, and even if there were parts of me that were familiar to human beings, my gradual deterioration would lead me further and further away, and in the end not even my family would know me.’

Janet Frame (1924–2004)

I sincerely thank all the persons who put their faith in me, those who participated and those who recruited for me. I am but a vessel for your information. I wish to thank all the physicians, mental health nurses and general good fairies who gave their time and assistance to supporting my goal and aspirations. I wish to acknowledge the lady suffering from cancer who so graciously shared her mangosteen secret, which she claimed improved her energy levels.

I especially wish to acknowledge the assistance of my supervisors Professors Kim Usher and Michael Berk, Dr Olivia Dean and Associate Professor Susan Cotton. Thanks also to Dr Tessa Cookson (mental health physician for the study), Dr Elizabeth Emmanuel (for assessing the safety of the study for its duration), Sue Richmond (for monitoring the clinical trial) and Megan Marriot (the clinical trial pharmacist). Thanks to Professor Lois Salamonsen, Jenny Hercus, Stella Green, Dr Jenny Sando, Dr Duncan Adams and Associate Professor Mary Hercus-Rowe, whose kindness made this research possible. Thank you to Professor Joseph Brimacombe for facilitating my research path and the late Mervyn Thompson for mentoring my writing skills. I most of all wish to thank my husband Gelly Laupu and sons, Max and Gordon, who endured the PhD process, at times going without because of it.
Statement on the Contribution by Others

**Fees:** Nil

**Stipend Support:** Australian Postgraduate Award, plus $5000 per annum top up from the School of Nursing, Midwifery and Nutrition.

**Supervision:** Kim Usher, Michael Berk, Olivia Dean and Susan Cotton.

**Other collaborations:** Dr Elizabeth Emmanuel (safety monitor), Sue Richmond (clinical trial monitor), Meagan Marriot (clinical trial pharmacist) and Alemka Russell from Queensland Health. Also consumer advocates, participant physicians and study participants.

**Statistical support:** Associate Professor Susan Cotton. Initial assistance was received from Emeritus Professor Rhondda Jones, Angela Reid and Associate Professor Petra Buettner.

**Editorial assistance:** Elite editing.

**Research assistance:** Dr Tessa Cookson for medical administration.

**Any other assistance:** Mentoring was received from Professor Lois Salamonsen. Paid assistance was received from Georgina Twoomey, Meagan Marriot (pharmacists), Courtney Butler (clinical trials coordinator for Sullivan-Nicolaides blood collection laboratories).

**Project funding:** The project sponsor was James Cook University, who contributed funding via the Graduate Research School and the School of Nursing, Midwifery and Nutrition. External funding was received from Mangosteen Dietary Supplements and the Far North Queensland Hospital Foundation.

**Use of infrastructure external to JCU:** External supervisors at Deakin University, Barwon Health and Orygen Research Centre, Queensland Health Clinical Research Unit at Cairns Hospital, Good Price Pharmacy at 318 Mulgrave Road, Cairns (compounding), Sullivan Nicolaides Laboratories, private vehicle, mobile telephone, treating physicians.
Use of infrastructure external to organisational unit within JCU: Initial statistical support, Postgraduate Centre computer, printing facilities and desk.
Specific Contributions to the Clinical Trial

Approvals

The research presented and reported in this thesis was conducted in accordance with the National Health and Medical Research Council (NHMRC) National Statement on Ethical Conduct in Human Research, 2007. The proposed research study received human research ethics approval from the James Cook University Human Research Ethics Committee (approval number C9). Direction for approvals was provided to Wendy Laupu by Dr Olivia Dean and Sue Richmond. Professor Michael Berk and Dr Olivia Dean assisted Wendy Laupu with the preparation of the National Ethics Application Form application. Suzie Grinter lent Wendy Laupu the use of her computer at a time when Wendy’s work space was under renovation. The ethics submissions were prepared by Wendy Laupu, edited by Professor Kim Usher and signed off by Associate Professor Lee Stewart. The Therapeutic Goods Administration submission was managed by Wendy Laupu. The subsequent Australian and New Zealand clinical trial registration was conducted by Wendy Laupu with guidance from Dr Olivia Dean.

Education

Direction for learning how to apply the outcome measures was provided by Professor Michael Berk and Dr Olivia Dean. Education for the use of the Positive and Negative Syndrome Scale was provided to Wendy Laupu by Alemka Russell (psychologist) at Queensland Health. A consent form template was provided by Stella Green (Queensland Health). Initial guidance was received from Professor Kim Usher. Thesis preparation was guided by Professor Michael Berk, Dr Olivia Dean and Associate Professor Susan Cotton (statistics) who specialise in similar clinical trials. Professor Lois Salamonsen provided mentoring assistance (thesis layout for efficacy
studies). Professors Kim Usher and Michael Berk, Associate Professor Susan Cotton and Dr Olivia Dean assisted with edits of the thesis.

**Recruitment**

Recruitment was managed by Wendy Laupu with the aid of many hands. Initially posters advertised the study and treating physicians were alerted to the study by letter. This occurred across 25 towns in the targeted region. Organisations and individuals who advertised initially for the study were public and private health centres, pharmacies, Lifeline, Centre-link, health food stores, churches, non-government organisations, the Honorable Curtis-Pitt, homeless outreach groups, psychologists, supermarkets, libraries, the Returned Services League and Queensland Health staff (outside working hours). Anyone who was willing was recruited for word of mouth advertising. A special mention and word of thanks must go to Pamela Valenti, Jeff Guest, Mike Scrase and Cliff Timmins for all of their hard work. Treating physicians were asked to screen potential participants.

**Study**

Supervision for the PhD candidate Wendy Laupu and administration for the study was conducted by Professor Kim Usher. This included financial administration, oversight of all aspects of the study and necessary contractual arrangements. Project funding was obtained by Wendy Laupu and contractual arrangements were made and managed by Professor Kim Usher, Associate Professor David Lindsay and James Cook University’s legal representative, Jasper Taylor. Clinical trial insurance was obtained by Wendy Laupu through James Cook University. Wendy Laupu managed the conduct of the study, which involved liaison with the compounding pharmacy (Georgina Twomey), Sullivan-Nicolaides clinical trial coordinator (Courtney Butler) and clinical trial pharmacist (Meagan Marriot). Blinding, randomisation, dispensing, labelling for the clinical trial and recording were conducted by Meagan Marriot.
Safety monitoring was undertaken by Dr Elizabeth Emmanuel, and the internal monitor was Dr Tessa Cookson. Dr Cookson acted as the study physician to monitor any concerns and for medical administration such as prescriptions, laboratory forms and crosschecking of Wendy Laupu’s field work. The 305 interviews were conducted by Wendy Laupu. Start-up meetings were initiated by Professor Michael Berk and Dr Olivia Dean. Closedown meetings were undertaken by Wendy Laupu. Dr Tessa Cookson signed off on matters pertaining to the medical administration of the trial (blood forms, prescribing of the intervention and crosschecking of the fieldwork). Professor Kim Usher and Dr Tanya Park signed off on matters pertaining to clinical trial supervision and original data. Dr Elizabeth Emmanuel signed off with regards to the safe delivery of the intervention. Meagan Marriot signed off on the clinical trial logs (compliance, blinding, randomisation, dispensing and labelling).

**Statistical analyses**

Associate Professor Petra Buettner checked the power analysis calculation. Professor Michael Berk directed Wendy Laupu to utilise mixed model repeated measures (MMRM) for the modelling of statistical analysis under the guidance of Associate Professor Sue Cotton. Emeritus Professor Rhondda Jones provided information for Wendy Laupu to set up the MMRM analysis. Planning and the checking of the *post hoc* and other statistical analyses were provided by Associate Professor Susan Cotton. Susan Jaccups provided some statistical direction; however, it differed from acceptable analysis of clinical trials in psychiatry. The statistical analysis itself was conducted by Wendy Laupu using the SPSS20 program.
Abstract

**Background:** Current treatments for schizophrenia, while effective, often lead to partial functional recovery for affected individuals. The neurobiology of schizophrenia consists of a complex array of factors whose interplay is not well understood. As a consequence, schizophrenia remains sub-optimally treated by existing therapeutic options. With a paucity of available novel therapies for schizophrenia and a lack of biologically driven targets being explored by pharmaceutical companies, there is a need for investigator-initiated trials examining novel pathways for the reduction of core symptoms and improved functionality. A review of the literature identifies the presence of mitochondrial dysfunction, oxidative stress and impaired redox defenses such as reduced glutathione levels and impaired antioxidant enzymes (glutathione S-transferase) in the primary disorder. Secondary metabolites in mangosteen pericarp are hypothesised to protect against oxidative stress by evoking an intrinsic pathway including mitochondria. It is unclear whether mangosteen pericarp may affect the severity of negative and positive symptoms and cognitive and social functioning in schizophrenia. These symptom domains are known to persist despite wide use of existing treatment options. The current study aims to assess whether adjunctive treatment with mangosteen pericarp influences these residual symptom domains in individuals with schizophrenia.

**Methods:** A randomised, placebo-controlled adjunctive trial was conducted. Structured interviews using the Mini International Neuropsychiatric Interview (MINI-plus) were conducted to establish the diagnosis of schizophrenia or schizoaffective disorder. The efficacy of the intervention on symptom domains was assessed using established outcome measures, consisting of structured interviews at baseline, 90 days, 150 days and 180 days. The primary outcome measure was the Positive and Negative Syndrome Scale (PANSS) total score, with secondary measures including the PANSS subscales (positive, negative and general), the
Montgomery Asberg Depression Rating Scale (MADRS), the Clinical Global Impression Improvement (CGI-I) and Severity scales (CGI-S), the Abnormal Involuntary Movement Scale (AIMS), the Self-Rated Life Satisfaction Scale (SRLS), the Liverpool University Neuroleptic Side Effect Rating Scale (LUNSERS) and the Global Assessment of Functioning (GAF). It was hypothesised that adjunctive mangosteen pericarp would reduce symptoms of schizophrenia indexed by PANSS total scores compared to placebo. The study followed Good Clinical Practice and National Health and Medical Research Council guidelines for clinical trials. Participants were randomly allocated to either 1000mg/day of encapsulated *Garcinia mangostana* L. (mangosteen) pericarp powder or a matching placebo for a period of 180 days, in addition to treatment as usual.

**Results:** The primary and secondary measures were assessed at each interview. The placebo and experimental group had statistically significant differences between groups on the primary and secondary outcomes at the 180-day endpoint. The efficacy of mangosteen pericarp was supported by a high level of compliance and significant difference of the primary indicator, PANSS total (*p* < 0.01), with a large effect size (1.41) between groups at endpoint.

Secondary measures demonstrated significant between-group differences across all measures of dimensional outcome: PANSS positive (*p* < 0.01), PANSS negative (*p* < 0.01), PANSS general (*p* < 0.01), MADRS (*p* = 0.01) and CGI-S (*p* = 0.03). Functioning and well-being measures were significantly different between groups for SRLS (*p* < 0.01) and GAF (*p* = 0.03). The effect of treatment over time was different between groups, as measured by CGI-I (*p* < 0.01). Side-effect rating across LUNSERS scores indicated significant between-group differences (*p* < 0.01), with greater reduction in the mangosteen pericarp group. There were non-significant differences between groups of tardive dyskinesia (*p* = 0.16) measured by AIMS scores. Tobacco and alcohol use did not differ between groups at 180 days. Mangosteen pericarp was well tolerated.
Conclusions: Our data supports a causal relationship between mangosteen pericarp and a reduction of symptom domains associated with schizophrenia. Our results support the efficacy of 1000mg/day encapsulated mangosteen pericarp compared to the placebo for the treatment of schizophrenia and schizoaffective disorder.

Australian and New Zealand Clinical Trial Registration number: ACTRN12611000910909.
2.5. Oxidative stress ................................................................................. 30
  2.5.1. Nitrosative stress in schizophrenia ............................................. 31
  2.5.2. Lipid peroxidation in schizophrenia .......................................... 31
  2.5.3. Reduced levels of glutathione in schizophrenia ....................... 32
  2.5.4. Reduced levels of glutathione S-transferase in schizophrenia .... 33
2.6. Implications for neuronal health ....................................................... 33
2.7. Effect on symptom domains ............................................................. 36
  2.7.1. Impact on unwanted effects of second-generation antipsychotic
        drugs ....................................................................................... 38
2.8. Alternative therapies ........................................................................ 39
2.9. Rationale for testing mangosteen pericarp ...................................... 44
2.10. Secondary metabolites .................................................................... 44
  2.10.1. Antioxidant activity .................................................................. 45
  2.10.2. Neurobiology nexus attributed to mangosteen pericarp and
          schizophrenia ............................................................................ 47
2.11. Safety of mangosteen pericarp ........................................................ 49
2.12. Research aims ................................................................................. 52
2.13. Research hypothesis ........................................................................ 53
2.14. Summary ......................................................................................... 53

Chapter 3: Methodology and Study Design ............................................ 55
3.0. Introduction ....................................................................................... 55
3.1. Participants ........................................................................................ 56
3.2. Inclusion and exclusion criteria ........................................................ 58
3.3. Withdrawal criteria ........................................................................... 59
3.4. Measurements ................................................................................... 60
  3.4.1. Participant demographics ........................................................... 62
  3.4.2. Outcome measures ..................................................................... 62
3.5. Study procedure ................................................................................ 68
  3.5.1. Ethical and legal consideration ................................................... 69
  3.5.2. Registration number and protocol .............................................. 70
  3.5.3. Funding sources ........................................................................ 70
  3.5.4. Sample size ............................................................................... 71
  3.5.5. Presentation of the intervention .................................................. 71
  3.5.6. Mangosteen pericarp .................................................................. 72
  3.5.7. Placebo ..................................................................................... 73
  3.5.8. Setting ....................................................................................... 74
  3.5.9. Study locations for data collection ............................................. 74
  3.5.10. Data management .................................................................... 74
3.6. Statistical methods ............................................................................ 75
3.7. Summary ........................................................................................... 77

Chapter 4: Results ..................................................................................... 78
4.0. Introduction ....................................................................................... 78
4.1. Overview of the study ....................................................................... 79
4.2. Demographics of the study sample .................................................. 82
List of Tables

Table 1: Compiled list of second-generation antipsychotic drugs available in Australia at the time of the clinical trial ......................................................... 5

Table 2: Some unwanted effects associated with second-generation antipsychotic drugs ............................................................ 8

Table 3: Selection of tests commonly used to assess schizophrenia .... 37

Table 4: RCT/open label studies reporting nutraceuticals tested in schizophrenia (2005-2014) ..................................................................................... 40

Table 5: Studies orally administering compounds of mangosteen pericarp in humans to date ................................................................................. 51

Table 6: Outcome measure guide .................................................................................................................. 66

Table 7: Characteristics of interest, and statistical analysis of each group at baseline (n = 80) .............................................................................. 86

Table 8: Overall and between-group descriptive analysis ($M[SD]$) for baseline clinical and functioning measures (n = 80) ........................................ 88

Table 9: Completion rates at 90, 150 and 180 days (n = 80) ................. 89

Table 10: Comparison of completers and non-completers over the 180 days of the trial .................................................................................................. 91

Table 11: Effect sizes for outcome measures (difference between baseline and 180 days) .................................................................................. 105

Table 12: Safety data for the clinical trial (n = 80) .................................. 106

Table 13: Response as represented by percentage reduction in symptoms from baseline to 180 days as measured by PANSS total scores .......... 107
List of Figures

Figure 1: *Garcinia mangostana* L. tree bearing unripened fruit ..................10
Figure 2: Mangosteen pericarp surrounding the white flesh of the fruit segments ........................................................................................................11
Figure 3: Structure of alpha mangostin..........................................................12
Figure 4: The chemical structure of epicatechin............................................42
Figure 5: Parallel-group two-armed study design for an RCT .................55
Figure 6: Visit schedule..................................................................................61
Figure 7: Participant flow analysis of the primary outcome measure ......81
Figure 8: Mean estimate and standard error scores for PANSS total in each group, across interviews and over time........................................93
Figure 9: Mean estimate and standard error scores for PANSS positive in each group, across interviews and over time.................................95
Figure 10: Mean estimate and standard error scores for PANSS negative in each group, across interviews and over time ................................96
Figure 11: Mean estimate and standard error scores for PANSS general in each group, across interviews and over time .............................97
Figure 12: Mean estimate and standard error scores for Montgomery-Asberg Depression Rating Scale in each group, across interviews and over time . ..........................................................98
Figure 13: Mean estimate and standard error scores for CGI-S in each group, across interviews and over time ........................................99
Figure 14: Mean estimate and standard error scores for GAF in each group, across interviews and over time ........................................100
Figure 15: Mean and standard deviation scores for CGI-I in each group, across interviews and over time ...............................101
Figure 16: Mean estimate and standard error scores for SRLS in each group, across interviews and over time .........................................102
**Figure 17:** Mean estimate and standard error scores for LUNSERS in each group, across interviews and over time ................................................................. 103

**Figure 18:** Mean estimate and standard error scores for AIMS in each group, across interviews and over time ................................................................. 104

**Figure 19:** Mean estimate and standard error scores(item 10) from the MADRS for suicidal ideations in each group, across interviews and over time 108

**Figure 20:** Mean estimate and standard error scores for anxiety (item G2) from the PANSS in each group, across interviews and over time…….. 109

**Figure 21:** Mean estimate and standard error scores for PANSS total in SGA drug non-adherent participants in each group, across interviews and over time ......................................................................................................................... 112

**Figure 22:** Mean estimate and standard error scores for PANSS positive in SGA drug non-adherent participants in each group, across interviews and over time ......................................................................................................................... 112

**Figure 23:** Mean estimate and standard error scores for PANSS negative in SGA drug non-adherent participants in each group, across interviews and over time ......................................................................................................................... 113

**Figure 24:** Mean estimate and standard error scores for PANSS general in SGA drug non-adherent participants in each group, across interviews and over time ......................................................................................................................... 113

**Figure 25:** Mean estimate and standard error scores for MADRS in SGA drug non-adherent participants in each group, across interviews and over time ......................................................................................................................... 113

**Figure 26:** Mean estimate and standard error scores for CGI-S in SGA drug non-adherent participants in each group, across interviews and over time 114

**Figure 27:** Mean estimate and standard error scores for GAF in SGA drug non-adherent participants in each group, across interviews and over time 114

**Figure 28:** Mean estimate and standard error scores for SRLS in SGA drug non-adherent participants in each group, across interviews and over time 115
Figure 29: Mean estimate and standard error scores for LUNSERS in SGA drug non-adherent participants in each group, across interviews and over time ................................................................. 115

Figure 30: Mean estimate and standard error scores for AIMS in SGA drug non-adherent participants in each group, across interviews and over time 116
MMRM  Mixed model repeated measures
mTOR         Mammalian Target Of Rapamycin
NHMRC        National Health and Medical Research Council
PANSS        Positive and Negative Syndrome Scale
%            Percentage
RCT          Randomised controlled trials
Redox        Reduction-oxidation Reaction
RNA          Ribonucleic acid
SANS         Scale of Assessment of Negative Symptoms
SD           Standard deviation
SGA          Second-generation antipsychotic drug
SRLS         Self-Rated Life Satisfaction Scale
t-test        Independent samples t-test
THC          tetrahydrocannabinol